comparemela.com
  1. Home
  2. Live Updates
  3. Prnewswire Leap Therapeutics Inc - Breaking News

Latest Breaking News On - Prnewswire leap therapeutics inc - Page 6 : comparemela.com

Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United kingdomNew zealandMatthew deyoungDouglase onsiPrnewswire leap therapeutics incSecurities exchangeBeigene ltdLeap therapeutics incChief executive officerRaymond james institutional investors conferencePresentation detailsLeap therapeuticsSecurities actSecurities exchange actPrivate securities litigation reform actLeap therapeutics

Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United kingdomNew zealandMatthew deyoungDouglase onsiPrnewswire leap therapeutics incSecurities exchangeBeigene ltdLeap therapeutics incChief executive officerRaymond james institutional investors conferencePresentation detailsLeap therapeuticsSecurities actSecurities exchange actPrivate securities litigation reform actLeap therapeutics

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced.

United statesNew zealandUnited kingdomSouth koreaRepublic of koreaMatthew deyoungDouglase onsiSamuel klempnerSamuelj klempnerAmerican society of clinical oncologyHospital cancer centerDrug administrationBeigene ltdHarvard medical schoolProfessor at harvard medical schoolPrnewswire leap therapeutics inc

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced.

United statesNew zealandUnited kingdomSouth koreaRepublic of koreaMatthew deyoungDouglase onsiSamuel klempnerSamuelj klempnerAmerican society of clinical oncologyHospital cancer centerDrug administrationBeigene ltdHarvard medical schoolProfessor at harvard medical schoolPrnewswire leap therapeutics inc

Leap Therapeutics to Present at H C Wainwright BioConnect 2022 Conference

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United kingdomNew zealandMatthew deyoungDouglase onsiHc wainwright bioconnectPrnewswire leap therapeutics incSecurities exchangeBeigene ltdLeap therapeutics incChief executive officerLeap therapeuticsSecurities actSecurities exchange actPrivate securities litigation reform actLeap therapeuticAnnual report

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.